Next Article in Journal
Angiogenesis in Pancreatic Cancer: Pre-Clinical and Clinical Studies
Next Article in Special Issue
Limited Sensitivity of Circulating Tumor DNA Detection by Droplet Digital PCR in Non-Metastatic Operable Gastric Cancer Patients
Previous Article in Journal
Bimodal Radiotherapy with Active Raster-Scanning Carbon Ion Radiotherapy and Intensity-Modulated Radiotherapy in High-Risk Nasopharyngeal Carcinoma Results in Excellent Local Control
Previous Article in Special Issue
Molecular Subtype Conversion between Primary and Metastatic Breast Cancer Corresponding to the Dynamics of Apoptotic and Intact Circulating Tumor Cells
Open AccessArticle

Phenotypic Characterization of Circulating Lung Cancer Cells for Clinically Actionable Targets

1
The School of Biomedical Sciences, Room 603D, Institute of Health and Biomedical Innovation, Queensland University of Technology, 60 Musk Avenue, Kelvin Grove, QLD 4059, Australia
2
Translational Research Institute, Brisbane, QLD 4102, Australia
3
Department of Anatomical Pathology, Pathology Queensland, Brisbane, QLD 4006, Australia
4
Princess Alexandra Hospital, Woolloongabba, QLD 4102, Australia
5
The School of Biomedical Engineering, University of Technology Sydney, Ultimo, NSW 2007, Australia
6
Department of Biomedical Engineering, Institute of Molecular Medicine, Sechenov First Moscow State Medical University, Moscow 119991, Russia
*
Author to whom correspondence should be addressed.
Cancers 2019, 11(3), 380; https://doi.org/10.3390/cancers11030380
Received: 28 February 2019 / Revised: 14 March 2019 / Accepted: 14 March 2019 / Published: 18 March 2019
(This article belongs to the Special Issue Liquid Biopsy for Cancer)
Objectives: In non-small cell lung cancers (NSCLC), tumour biopsy can often be an invasive procedure. The development of a non-invasive methodology to study genetic changes via circulating tumour cells (CTCs) is an appealing concept. Whilst CTCs typically remain as rare cells, improvements in epitope-independent CTC isolation techniques has given rise to a greater capture of CTCs. In this cross sectional study, we demonstrate the capture and characterization of NSCLC CTCs for the clinically actionable markers epidermal growth factor receptor (EGFR) alterations, anaplastic lymphoma kinase (ALK) rearrangements and programmed death ligand-1 (PD-L1) expression. The study identified CTCs/CTC clusters in 26/35 Stage IV NSCLC patients, and subsequently characterized the CTCs for EGFR mutation, ALK status and PD-L1 status. This pilot study demonstrates the potential of a non-invasive fluid biopsy to determine clinically relevant biomarkers in NSCLC. View Full-Text
Keywords: liquid biopsy; circulating tumour cells; non-small cell lung cancer; actionable mutations liquid biopsy; circulating tumour cells; non-small cell lung cancer; actionable mutations
Show Figures

Figure 1

MDPI and ACS Style

Kulasinghe, A.; Kapeleris, J.; Cooper, C.; Warkiani, M.E.; O’Byrne, K.; Punyadeera, C. Phenotypic Characterization of Circulating Lung Cancer Cells for Clinically Actionable Targets. Cancers 2019, 11, 380. https://doi.org/10.3390/cancers11030380

AMA Style

Kulasinghe A, Kapeleris J, Cooper C, Warkiani ME, O’Byrne K, Punyadeera C. Phenotypic Characterization of Circulating Lung Cancer Cells for Clinically Actionable Targets. Cancers. 2019; 11(3):380. https://doi.org/10.3390/cancers11030380

Chicago/Turabian Style

Kulasinghe, Arutha; Kapeleris, Joanna; Cooper, Carolina; Warkiani, Majid E.; O’Byrne, Kenneth; Punyadeera, Chamindie. 2019. "Phenotypic Characterization of Circulating Lung Cancer Cells for Clinically Actionable Targets" Cancers 11, no. 3: 380. https://doi.org/10.3390/cancers11030380

Find Other Styles
Note that from the first issue of 2016, MDPI journals use article numbers instead of page numbers. See further details here.

Article Access Map by Country/Region

1
Search more from Scilit
 
Search
Back to TopTop